News and blogs
166 results found.
New life-changing myeloma drug given positive recommendation for fourth-line use on the NHS for those ‘exhausting’ options
The drug teclistamab (Tecvayli), has been recommended by NICE to treat myeloma, a form of blood cancer, in England and Wales.
Why at Blood Cancer UK we think the new investment towards improving cancer detection from the government is promising
The government has announced a number of new partnerships backed by public and private sector investment to tackle cancer and other life-threatening diseases with faster diagnoses and better treatments, deploying innovative technologies and approaches.
Dr Jewel Cobb – cancer researcher and champion of equality
Dr Jewel Plummer Cobb was an African American cell biologist and physiologist who contributed to pioneering research into cancer treatment.
A step forward for people with blood cancer
The drug quizartinib is now available for people with this specific form of blood cancer on the NHS in England.
World Cancer Research Day: our new research projects
We are funding eight new research projects we are funding taking our total number of research projects to 87 across the UK.
Take at home tablet approved for blood cancer on NHS England
Zanubrutinib, is now available on the NHS in England for those with a type of blood cancer called marginal zone lymphoma.,
Drug, dasatinib approved for use on the NHS in Scotland
Dasatinib, is now approved for the treatment of adults with a form of leukaemia - Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) - on the NHS in Scotland.
New class of drug approved for myeloma in England and Wales
The very first bispecific drug for myeloma, elranatamab has been approved for restricted use in England and Wales as a fourth-line treatment.
New blood test for myeloma being researched at Birmingham
Two doctors at the University of Birmingham are developing a new technique to help diagnose and monitor people with the blood cancer, non-measurable myeloma.
Scotland approves two new blood cancer drugs
Two new drugs for the blood cancer, diffuse large B-cell lymphoma DLBCL have been made available for use on the NHS in Scotland as a third-line treatment.
Blood cancer treatment for a form of acute myeloid leukaemia approved for use on NHS
New blood cancer treatment for acute myeloid leukaemia (AML) with IDH1 mutation. The National Institute for Health and Care Excellence (NICE) approved Ivosidenib (Tibsovo) with azacitidine has made it available to those in England and Wales.
COVID-19 vaccines and blood cancer latest evidence
Lots of information continues to circulate about COVID-19 and vaccinations for immunocompromised people. Here's the latest evidence.
Selinexor recommended in draft final guidance for myeloma
The drug, selinexor has been recommended by NICE in final draft guidance for use in people with myeloma if previous treatment has failed.
How a Yorkshire house led to five pioneering research projects
Last year you raised an incredible £1.95m for Blood Cancer UK in the Omaze Millon Pound House Draw. Find out more about the incredible research projects this is helping to support.
Simon Thomas launches new blood cancer projects
Blood Cancer UK reveals that the money from their latest partnership with Omaze UK is their largest single donation to date. The money has now been invested into research via the Omaze x Blood Cancer UK Research Fund.
Scotland drug regulators rule blood cancer isn't cost effective
Yescarta, the blood cancer drug is not to be made available on the NHS in Scotland even though it is in England. Blood Cancer UK says it highlights the inequality in access to blood cancer drugs across the UK.
£4 million research project to establish those with high risk of blood cancer
On World Cancer Day, Blood Cancer UK & The Leukemia & Lymphoma Society announced a £4 million research project into establishing those at high risk of blood cancer.
Blood cancer drug Tepkinly authorised for use on NHS
The drug for diffuse large B-cell lymphoma, Tepkinly, has been authorised for use on the NHS as a third line treatment.
From despair to hope: The Matthew Wilson Multiple Myeloma Fund
Matthew Wilson establishes the Matthew Wilson Multiple Myeloma Fund (MWMMF) at Blood Cancer UK.
Research links childhood CT scan exposure to increased blood cancer risk
In new research, scientists have linked increased CT scan exposure to an increased risk of blood cancer in younger people.
